Conference Coverage

Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer

Featuring Brian M. Slomovitz, MD

03/18/2024

At the Society of Gynecological Oncology (SGO) 2024 Annual Meeting, Brian M. Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, discussed results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.

Results from this trial demonstrated tisotumab vedotin significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) when compared to chemotherapy among patients with second-/third-line recurrent or metastatic cervical cancer.

Source:

Slomovitz B, González-Martín A, Fujiwara K, et al. Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study. Presented at the Society of Gynecologic Oncology Annual Meeting; March 16-18, 2024. San Diego, California.

© 2024 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Blog

CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care

08/07/2024

Winston Wong , PharmD;

At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.

At CPC+CBEx, we bring together...

08/07/2024

Journal of Clinical Pathways

Videos

Chronic Lymphocytic Leukemia Treatment Updates

07/31/2024

Farrukh T. Awan , MD;

Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.

Farrukh Awan, MD, discusses some...

07/31/2024

Journal of Clinical Pathways

Breaking Down Health Care

Why People Should Care About How Health Care Works (Part 1)

07/29/2024

Michael Kolodziej , MD;

John Hennessy , MBA;

In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.

In part one of this two-part...

07/29/2024

Cancer Care Business Exchange

News

Examining Treatment Delay Trends in Patients With Lung Cancer

07/24/2024

Hannah Musick ;

A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.

A study in Missouri uncovers a...

07/24/2024

Journal of Clinical Pathways

Commentary

The Role of Bioimpedance Spectroscopy in Standardizing Lymphedema Clinical Pathways

07/24/2024

Lymphedema is a frequently overlooked complication affecting cancer survivors, occurring when normal lymphatic drainage is disrupted, leading to the buildup of protein-rich lymph fluid in the interstitial space. If left untreated, it can...

Lymphedema is a frequently...

07/24/2024

Journal of Clinical Pathways

Insights from the SGO Annual Meeting on Women’s Cancer

Tisotumab Vedotin Improved Survival Outcomes Among Patients With Recurrent or Metastatic Cervical Cancer

Source:

© 2024 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products